MedTrace Logo

To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers

NCT06378684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-04-22

No results posted yet for this study

Summary

The objective is to evaluate the safety and Pharmacokinetic Interactions after adminitration drug(Treatment A or B or A+B) in Healthy Volunteers

Conditions

  • Healthy

Interventions

DRUG

Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Sponsors & Collaborators

Principal Investigators

  • MinSoo Kim · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-10
Primary Completion
2023-12-23
Completion
2024-01-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06378684 on ClinicalTrials.gov